Amgen’s Q4 tops views, but 2023 guidance falls on lower end of expectations

Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations.